Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation From an Ongoing Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients At ESMO Breast Cancer Meeting 2022

Rhizen Pharma reports encouraging initial results from an ongoing phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K d/? inhibitor with additional SIK3 inhibitory activity)

Related Keywords

Germany ,Switzerland ,Berlin ,Samyukta Bhagwati ,Kostenloser Wertpapierhandel ,Swaroop Vakkalanka ,Rhizen Pharma ,Rhizen Pharmaceuticals ,Rhizen Pharmaceuticals Ag Contact ,Rhizen Pharmaceuticals Ag ,Corporate Affairs Communications ,Cancer Meeting ,Salt Inducible Kinase ,Track Orphan Drug Designations ,Rhizen ,Pharmaceuticals ,Nnounces ,Romising ,Interim ,Data ,Presentation ,Rom ,Ngoing ,Hase ,Study ,Enalisib ,P6530 ,Ocally ,Dvanced ,Metastatic ,Breast ,Dancer ,Patients ,Osmo ,Meeting ,022 ,